Insider Buying: PureTech Health (LON:PRTC) Insider Purchases £939.44 in Stock

PureTech Health plc (LON:PRTC) insider Robert Langer purchased 93,944 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were bought at an average cost of GBX 1 per share, with a total value of £939.44.

PureTech Health Stock Performance

LON PRTC opened at GBX 119.12 on Monday. PureTech Health plc has a fifty-two week low of GBX 104.71 and a fifty-two week high of GBX 146.40. The stock has a market cap of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33. The business has a fifty day moving average of GBX 127.34 and a 200-day moving average of GBX 126.62.

Analysts Set New Price Targets

Separately, Peel Hunt restated a “buy” rating and set a GBX 508 target price on shares of PureTech Health in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, PureTech Health currently has a consensus rating of “Buy” and an average target price of GBX 508.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.